



Verastem Oncology to Present at the H.C. Wainwright BioConnect 2021 Conference

January 5, 2021

BOSTON--(BUSINESS WIRE)--Jan. 5, 2021-- Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the virtual H.C. Wainwright BioConnect 2021 Conference. The fireside chat will be made available for on-demand listening beginning Monday, January 11, 2021 at 6:00 a.m. EST.

The webcast of the fireside chat will be available on the "Media" section of the Company's website at www.verastem.com under "Events & Presentations".

About Verastem Oncology

Verastem Oncology (Nasdaq:VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and focal adhesion kinase (FAK) inhibition. For more information, please visit www.verastem.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210105005286/en/): <https://www.businesswire.com/news/home/20210105005286/en/>

Investors:

Ajay Munshi
VP, Corporate Development
+1 781-469-1579
amunshi@verastem.com

Media:

Lisa Buffington
VP, Corporate Communications
+1 781-292-4205
lbuffington@verastem.com

Source: Verastem, Inc.